Virology Unit, Viral Hepatitis Laboratory, Institut Pasteur du Maroc, Casablanca, Morocco.
Laboratoire de Biologieet Sante (URAC34), Departement de Biologie, Faculté des Sciences Ben Msik, Universite Hassan II de Casablanca, Morocco.
Curr Med Chem. 2018;25(23):2709-2721. doi: 10.2174/0929867325666180221141451.
Hepatitis B Virus (HBV) is a major global health burden. Interferon alpha and nucleos(t)ide analogues are currently the standard-of-care for chronic HBV infection. However, these antiviral agents have limited efficacy and do not result in a sustained virological response in the majority of infected patients. Virtual Screening (VS) strategies have now a strong impact on drug discovery, the strength of this research field has been corroborated by recent contributions in the development of novel drug candidates which are in clinical trials or which are already available in the clinics. In this context, different VS strategies have been applied to HBV in order to discover novel inhibitors. In this review, we summarize the VS efforts to identify and design novel HBV interventions. We believe that the combination of in silico and in vitro tools can lead to faster validation of novel drug targets which could accelerate the HBV drug discovery and development efforts.
乙型肝炎病毒 (HBV) 是全球主要的健康负担。干扰素α和核苷（酸）类似物是目前慢性 HBV 感染的标准治疗方法。然而，这些抗病毒药物的疗效有限，并且不能使大多数感染患者获得持续的病毒学应答。虚拟筛选 (VS) 策略现在对药物发现产生了重大影响，这一研究领域的实力得到了最近在开发新的候选药物方面的贡献的证实，这些药物正在临床试验中或已经在临床上使用。在这种情况下，已经应用了不同的 VS 策略来发现新型 HBV 抑制剂。在这篇综述中，我们总结了用于识别和设计新型 HBV 干预措施的 VS 研究。我们相信，计算和体外工具的结合可以加速新型药物靶点的验证，从而加速 HBV 药物发现和开发的努力。
